Cargando…

BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?

The Bacillus Calmette-Guerin vaccine (BCG vaccine) designed to prevent tuberculosis in children has been shown to induce a adaptive immune response in the body to fight against bacteria as well as other parasites and viruses. This knowledge has been reciprocated to generate the idea that this vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajarshi, Keshav, Chatterjee, Aroni, Ray, Shashikant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255206/
https://www.ncbi.nlm.nih.gov/pubmed/32835211
http://dx.doi.org/10.1016/j.medidd.2020.100049
_version_ 1783539688327348224
author Rajarshi, Keshav
Chatterjee, Aroni
Ray, Shashikant
author_facet Rajarshi, Keshav
Chatterjee, Aroni
Ray, Shashikant
author_sort Rajarshi, Keshav
collection PubMed
description The Bacillus Calmette-Guerin vaccine (BCG vaccine) designed to prevent tuberculosis in children has been shown to induce a adaptive immune response in the body to fight against bacteria as well as other parasites and viruses. This knowledge has been reciprocated to generate the idea that this vaccine can also offer protection against severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). Some recent pre-print articles have highlighted that countries with mass BCG immunizations seems to have a lower incidence of coronavirus disease 2019 (COVID-19) compared to those without BCG immunization. There are yet no experimental proof of any such association and the world health organisation (WHO) is currently testing the theory with clinical trials on selected cohorts. Epidemiologists and other scientific experts has expressed both their hope and concern simultaneously regarding the success theory of BCG vaccination to prevent COVID-19. Though its still not verified in any way whether the BCG vaccination can actually prevent COVID-19 or not but we believe a thorough analytical research in this regard is indeed worth a shot.
format Online
Article
Text
id pubmed-7255206
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-72552062020-05-28 BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope? Rajarshi, Keshav Chatterjee, Aroni Ray, Shashikant Med Drug Discov Article The Bacillus Calmette-Guerin vaccine (BCG vaccine) designed to prevent tuberculosis in children has been shown to induce a adaptive immune response in the body to fight against bacteria as well as other parasites and viruses. This knowledge has been reciprocated to generate the idea that this vaccine can also offer protection against severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). Some recent pre-print articles have highlighted that countries with mass BCG immunizations seems to have a lower incidence of coronavirus disease 2019 (COVID-19) compared to those without BCG immunization. There are yet no experimental proof of any such association and the world health organisation (WHO) is currently testing the theory with clinical trials on selected cohorts. Epidemiologists and other scientific experts has expressed both their hope and concern simultaneously regarding the success theory of BCG vaccination to prevent COVID-19. Though its still not verified in any way whether the BCG vaccination can actually prevent COVID-19 or not but we believe a thorough analytical research in this regard is indeed worth a shot. The Authors. Published by Elsevier B.V. 2020-09 2020-05-26 /pmc/articles/PMC7255206/ /pubmed/32835211 http://dx.doi.org/10.1016/j.medidd.2020.100049 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Rajarshi, Keshav
Chatterjee, Aroni
Ray, Shashikant
BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?
title BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?
title_full BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?
title_fullStr BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?
title_full_unstemmed BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?
title_short BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?
title_sort bcg vaccination strategy implemented to reduce the impact of covid-19: hype or hope?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255206/
https://www.ncbi.nlm.nih.gov/pubmed/32835211
http://dx.doi.org/10.1016/j.medidd.2020.100049
work_keys_str_mv AT rajarshikeshav bcgvaccinationstrategyimplementedtoreducetheimpactofcovid19hypeorhope
AT chatterjeearoni bcgvaccinationstrategyimplementedtoreducetheimpactofcovid19hypeorhope
AT rayshashikant bcgvaccinationstrategyimplementedtoreducetheimpactofcovid19hypeorhope